Search Weight Loss Topics:

Page 88«..1020..87888990..100..»

Home » Testosterone » Page 88

Mens Journal aims to feature only the best products and services. We update when possible, but deals expire and prices can change. If you buy something via one of our links, we may earn a commission.Questions? Reach us at shop@mensjournal.com.

We all need a boost once in a while. If youre having trouble dropping those last few pounds, maintaining a ripped physique, or just motivating to get off the couch and work out, try Modern Man v.3 Intense 2-in-1 Thermogenic and Testosterone Support.

This is far more than your typical testosterone booster. Modern Man delivers fast-acting results you can see and feel, ultimately enhancing your flow state to keep you in the zone and reach your fitness goals. If youre looking to get ripped, this is the stuff you need to take your fitness over the top. It transcends both testosterone boosters and fat burners.

If you find yourself in an endless cycle of stress, fatigue, and irritability, rest assured youre not alone. All guys go through this. How do some men stay positive, energized and focused? Modern Man can help.

A constant state of stress can torpedo your natural testosterone production. With less testosterone, youre more prone to store fat, have trouble building muscle, experience brain fog, and lose your drive.

With muscle-preserving, fat-burning ingredients and natural testosterone support, bodybuilding experts and business professionals alike swear by Modern Man. Its formulated with a very specific purpose: to help you reach your fitness goals. Getting in shape and achieving your goals adds confidence, which aids in natural testosterone production.

So break the cycle of stress and fatigue. Get Modern Man.

Its more than just testosterone. By combining some of the top, most researched ingredients recommended by professional biohackers, Modern Mans focus-enhancing complex provides a daily brain boost. Multiple nootropics work to boost cognitive function and increase your attention to detail. You will bust out of whats known as brain fog and feel more alert and energetic in your mind. And that will help you be more energetic physically.

And its more than just a brain boost. Modern Man uses clinically studied ingredients like KSM 66, ashwagandha, and Eurycoma Longifolia to support your lean physique and unleash raw power.

And its is made for daily use. So even if youre frequently on-the-go or traveling, you can still supply your body with what it needs on a daily basis to stay strong.

Modern Man will help you optimize your bodys capacity for stress relief, too. So negative thoughts and anxiety cant bring you down. Youll feel calmer in the face of adversity and boost your mood because Modern Man supports healthy dopamine production to further keep you in a positive state of mind.

With over 1,200 reviews and an impressive 4.3-star rating by real users, its safe to say that Modern Man works for a ton of men. Break out of your downward spiral, and be the Modern Man you were born to be.

Check out all the great products and gear we recommend to Mens Journal readers

SEE ALSO:

How to Buy the Perfect Suit for You

The Best Jerky (Beef and Beyond) You Can Buy

For access to exclusive gear videos, celebrity interviews, and more, subscribe on YouTube!

Read the original post:
Crush Your Fitness Goals with This Fat Burner and Testosterone Booster - Men's Journal

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (Acerus or the Company) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three- and nine-month period ended September 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (IFRS).

Third Quarter Highlights

In anticipation of the closing of the A&R Agreement, we have begun the process of standing-up both a US market access team and specialty sales organization to co-promote NATESTO to the United States market. This expansion of our footprint to enter the United States market confirms our mens health strategy and truly establishes Acerus as a globally focused company headquartered in Canada, not just a company servicing the Canadian marketplace, said Ed Gudaitis, President and Chief Executive Officer of Acerus. We are also excited about the results of a clinical study showing that NATESTO increases serum testosterone and improves symptoms while maintaining normal semen parameters in men with low testosterone. This positive study, presented initially by Dr. Ranjith Ramasamy, MD, Associate Professor and Director of Reproductive Urology at the University of Miami School of Medicine, at the American Society for Reproductive Medicine Conference on October 17, 2019, and subsequently at an Acerus Key Opinion Leader presentation in New York City on October 30, 2019, clearly differentiates NATESTO from other approved testosterone therapies. We are very excited by the outcomes of this study and will look to further develop the growing evidence-base supporting NATESTO.

Summary of Results for the Three Months Ended September 30, 2019 (compared to the Three Months Ended September 30, 2018 unless otherwise noted)

Total revenue in the quarter was negative $0.2 million compared to $1.6 million in the third quarter of 2018. This decline is due to a $0.8 million drop in Estrace and UrivarxTM product revenues and the net impact of $0.6 million in Q3-2019 for returns associated with the delay in returning NATESTO to the Canadian and South Korean markets (previously it was assumed that the product would be replaced rather than returned) and reversing the Q2-2019 $0.1 million charge to revenue discounts for incentives to customers to accept replacement product.

On August 2, 2019, we announced that we would voluntarily replace certain NATESTO lots released in the Canadian and South Korean markets, which was expected to cause temporary shortages in those markets. We have identified four commercial lots of NATESTO released in the Canadian and South Korean markets that were found to be non-conforming during long-term stability studies, even though such lots were fully in-specification at the time of release. This post-release non-conformity is not harmful to the patient, but may result in difficulties in dispensing. Acerus made minor modifications to the manufacturing process that appear to have resolved the previously identified issues and has produced a new commercial batch of Natesto. On November 1, 2019, we announced that Health Canada classified the changes as level I, requiring the submission of a SNDS. Should Health Canada utilize the full regulatory allotted time for reviewing a SNDS, Acerus would expect the Revised Batch to be released in the Canadian Market in Q1-2021. In Q2-2019, we had previously impaired inventory by $0.3 million and accrued $0.5 million related to replacing products, discounts and potential returns due to the issue described above. However, due to the additional delays, the Company reversed the previous accruals related to discounts and replacement of product and has accrued $0.7 million for returns in the current quarter.

The following table indicates the revenue by product for the quarter (in US$000s):

Difference

$

$ 80

$ 172

$ (92)

(159)

364

(523)

(296)

-

(296)

(375)

536

(911)

203

883

(680)

5

164

(159)

$ (167)

$ 1,583

$ (1,750)

Gross margin declined by $0.8 million to negative $0.04 million compared to the prior year quarter. The current figure reflects the accrual for product returns described above and the reversal of the $0.4 million charge to cost of goods made in Q2-2019 when it was expected that the Company would replace the recalled NATESTO product.

Selling, general and administrative expenses (SG&A) increased to $3.2 million from $2.2 million in the prior year period. The current quarter reflects costs of $2.1 million in anticipation of the NATESTO United States A&R Agreement closing and subsequent launch. Absent this charge, SG&A expenses were $1.1 million or 50% lower than the comparable prior year period, reflecting decreased marketing and selling expenses related to NATESTO Canada and UriVarxTM and decreased salaries and benefits costs due to reductions in commercial headcount and reductions in bonus accrual. The Company will continue to review expenses and make adjustments where necessary in light of the recent recall and SNDS requirement. In particular, Acerus will be streamlining its future operating expenses to focus on the following key priorities: 1) the standing up of the US organization in anticipation of the go-live of the A&R Agreement, 2) the approval by Health Canada and launch of avanafil in the Canadian market, 3) supporting our global partners who are launching NATESTO in their respective markets and 4) strengthening the management of our third-party manufacturing network.

Research and development ("R&D") expense was $0.6 million for the current quarter, a slight decline from the $0.8 million for the prior year period.

Earnings before interest, tax, depreciation and amortization (EBITDA)1 was a loss of $3.7 million compared to an EBITDA loss of $1.6 million for the prior year quarter. Adjusted EBITDA1, was a loss of $3.4 million for the quarter compared to a loss of $1.5 million for the prior year period.

The Company incurred a net loss of $4.6 million or $(0.02) per share for the quarter compared to a loss of $2.9 million or $(0.01) per share for the third quarter of 2018.

Cash as of September 30, 2019 was $4.1 million compared with $3.8 million on December 31, 2018, reflecting the proceeds of a CDN$4.5 million private placement in Q1-2019, and a US$5.0 million subordinated debt facility entered into in Q3-2019 between the Company and First Generation Capital Inc., a company affiliated with the Chairman of the Board of Directors of the Company, offset by cash used in operations.

Summary of Results for the Nine Months Ended September 30, 2019 (compared to the Nine Months Ended September 30, 2018 unless otherwise noted)

NATESTO USA UPDATE

As indicated above, the Company and Aytu Bioscience jointly announced on July 30, 2019, that they had signed an amended and restated license agreement to allow Acerus to enter the US market directly and co-promote NATESTO to the specialist (urology and endocrinology) market. Under the terms of the new agreement, Aytu returns the NDA for NATESTO in the US back to Acerus. Going forward, Acerus will assume all regulatory and clinical responsibilities and costs for the product in the US Acerus will take on a more expansive role in matters such as US marketing, reimbursement and medical strategy as part of the companies joint commercialization committee. Aytu will retain its primary care sales force and will continue to book all product net revenue while serving as the exclusive US supplier of NATESTO to wholesalers, pharmacies and other customers that receive a direct shipment. Financial payments will be based upon a tiered level of net revenue, post cost of goods sold (COGS), based on annual sales performance in the respective Acerus and Aytu Sales Channels. This transaction is conditional on Acerus raising at least US$10 million in any combination of debt or equity by no later than January 29, 2020. In anticipation of the condition being satisfied, the Company has begun working with its partner, Syneos Health, to facilitate a launch by Acerus in early 2020.

Conference Call

Shareholders are reminded that the conference call to discuss the Companys results for the three- and nine-month period ending September 30, 2019 will be held on Thursday, November 14, 2019 at 8:30 a.m. Eastern Time. To access the call live, please dial 416-340-2219 or 1-800-478-9326. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 11:59 p.m. Eastern Time on Thursday, November 21, 2019 by dialing 905-694-9451 or 1-800-408-3053, using access code: 2401991#.

About AcerusAcerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of mens health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the US and other territories.

Acerus shares trade on TSX under the symbol ASP and on the OTCQB under the symbol ASPCF. For more information, visit http://www.aceruspharma.com and follow us on Twitter and LinkedIn.

1 Non-IFRS Financial Measures - EBITDA and Adjusted EBITDAThe non-IFRS measures included in this press release are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. When used, these measures are defined in such terms as to allow the reconciliation to the closest IFRS measure. These measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from our perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. Despite the importance of these measures to management in goal setting and performance measurement, we stress that these are non-IFRS measures that may have limits in their usefulness to investors.

We use non-IFRS measures, such as EBITDA and Adjusted EBITDA to provide investors with a supplemental measure of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. We also believe that securities analysts, investors and other interested parties frequently use non-IFRS measures in the valuation of issuers. We also use non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets, and to assess our ability to meet our future debt service, capital expenditure and working capital requirements.

The definition and reconciliation of EBITDA and Adjusted EBITDA used and presented by the Company to the most directly comparable IFRS measures follows below:

EBITDA is defined as net (loss)/income adjusted for income tax, depreciation of property and equipment, amortization of intangible assets, interest on long-term debt and other financing costs, interest income, licensing revenue and changes in fair values of derivative financial instruments. Management uses EBITDA to assess the Companys operating performance.

Adjusted EBITDA is defined as EBITDA adjusted for, as applicable, royalty expenses associated with triggering events, milestones, share based compensation, impairment of intangible asset, foreign exchange (gain)/loss and the impact of charges related to a product recall. We use Adjusted EBITDA as a key metric in assessing our business performance when we compare results to budgets, forecasts and prior years. Management believes Adjusted EBITDA is an alternative measure of cash flow generation than, for example, cash flow from operations, particularly because it removes cash flow fluctuations caused by extraordinary changes in working capital. A reconciliation of net (loss)/income to EBITDA (and Adjusted EBITDA) is set out below.

2019

2018

2019

2018

$

(4,612

)

$

(2,871

)

$

(12,246

)

$

(13,735

)

-

2

-

2

177

447

642

1,300

64

Read more:
Acerus Reports Third Quarter and Year-to-Date Fiscal 2019 Financial Results - Business Wire

Through hormone replacement therapy, transgender women can receive estrogen to counteract testosterone and transgender men can receive testosterone to counteract estrogen, said Patricia Kress, the medical director of Student Health Service on campus.

Its a critical resource we have here on campus, Chris Jorgenson, the director of the Gender and Sexuality Resource Center, said.

Jorgenson said on campus, students are able to initiate hormone therapy if they have not yet done so prior to coming to campus, or are able to continue hormone therapy if they have already started elsewhere.

Its critical that we support trans people not only in social transitioning but if there are any medical transitions that they want to undertake, he said.

The mental health outcomes are incredible for people who are allowed to take steps to align themselves physically with who they are and how they identify, Jorgenson said.

If they are coming to Student Health Service on campus, visits are completely free, Kress said.

Right now if a transgender male comes in and needs this routine lab work done during a visit, the price is $74, Kress said.

The routine lab consists of checkups six months after the first meeting, 12 months out, and then once a year after that.

For transgender men, clinicians need to test testosterone levels to see if the medicine is working and to keep track of cholesterol, complete blood count, kidney function and blood sugar, she said.

The first year is a little expensive but once you get through that its not so bad, Kress said.

Outside of the university, that $74 panel would easily cost $700 to $1000, so here on campus, the treatment is much more inexpensive compared to other clinics, Kress said.

For transgender females, the blood tests are around $50 because we dont have to do that testosterone level, she said.

For some of these students whose parents cut them off, they have no financial support.

We dont want to make things harder for them by having the treatment be so expensive, Kress said.

The clinicians monitor the students feedback to the dosages very closely, Kress said.

When hormone therapy starts it can be a very exciting time but it also can be rocky with dips in the road, Kress said.

There are counseling services available throughout the process to make sure that the students receiving the treatment feel safe and supported and that the transgender students are doing whats best for them, Kress said.

Its kind of amazing because some students, after you give them that first dosage of the hormone they need, theyre like oh my gosh, a piece of the puzzle has been finally found. Its really powerful, she said. Kress spends a full hour with students at the first appointment, a half-hour at the next two meetings and then sees them in a follow-up within a month, she said.

We have plenty of time to be with them and not be rushed and to explore any concerns either of us would have the students or myself, Kress said.

Hormone therapy is not nearly as groundbreaking as people seem to believe, Jorgenson said, as prescribing hormones has been the norm for a long time.

Gender is very complicated, Jorgensen said.

There has been a lot of research conducted in order to further understand gender identity, whether it is merely the result of choices that we make or if it is a complex aspect of identity that is rooted in our brain, Jorgensen said.

One prominent hypothesis on the basis of gender dysphoria is that sexual differentiation of the genitals occurs separately from sexual differentiation of the brain in utero, making it possible that the body can veer in one direction and the mind in another, according to an article on The Scientist website, Are the Brains of Transgender People Different from Those of Cisgender People.

At the root of this idea is the notion that gender itselfthe sense of which category one belongs in, as opposed to biological sexis determined in the womb for humans, the article said.

We have been operating at this false assumption that ones body automatically presupposes their gender identity, Jorgenson said, and the research thus far since the early 90s just has not borne that out.

Erickson can be reached at [emailprotected]

Visit link:
Hormone therapy offered by Student Health Service - UWEC Spectator

November 15, 2019 (WORLD Magazine) Activists appear to have two approaches to controlling the narrative concerning transgender athletes' successes in women's sports: Attack the critics, or keep things hush-hush.

Neither has proven particularly effective at quelling a controversy that needn't exist, isn't going away, and really has only one solution.

Rachel (formerly Rhys) McKinnon went on the offensive after defending his 200-meter sprint title in the women's 3539 age group at the Masters Track Cycling Championships in Manchester, England, in late October. After setting a world record during qualifying, McKinnon won the race for the second straight year by four-tenths of a second, or roughly 15 meters in a race typically decided by centimeters.

In the wake of victory, McKinnon blasted those who decry the unfairness of biological males defeating women: "I have yet to meet a real champion who wants trans women banned," the 37-year-old Canadian said. "If you win because bigotry got your competition banned ... you're a loser."

Meanwhile, publicity handlers tried in vain to keep June (formerly Jonathan) Eastwood's transgender status quiet after the Big Sky Conference named the University of Montana cross-country runner its Female Athlete of the Week in late October. Eastwood received the honor after placing second in the women's race at Santa Clara University's Bronco Invitational in Sunnyvale, Calif.

In touting Eastwood's accolade, both the Big Sky and Montana websites failed to mention that Eastwood had competed as a male with moderate success as recently as last year. Eastwood's bio on the Montana women's cross-country website omits the senior's prior running experience entirely.

Something similar happened with CeCe (formerly Craig) Telfer of New Hampshire's Franklin Pierce University afterhe wonthe NCAA Division II title in the women's 400-meter hurdles last spring. And yet, Eastwood's transgender status, like Telfer's, still surfaced not least becauseThe Missoulian, the newspaper that covers Montana athletics in the university's home city of Missoula, ran a preseason profile hailing Eastwood's history-making turn as the NCAA's first openly transgender cross-country runner.

While Union Cycliste Internationale, cycling's international governing body, has a testosterone threshold that biological males cannot exceed if they wish to compete as women, the NCAA has none: The governing body for major-college sports simply requires biologically male athletes to take testosterone-suppressing hormones for at least one year. McKinnon and Eastwood have apparently done enough to comply with the rules of their sports' respective governing bodies.

Still, science is proving that even after taking testosterone-suppressing hormones, biologically male athletes retain competitive advantages over women:The Journal of Medical Ethicspublished a study in August stating that biological males do not lose significant muscle mass or power after suppressing their testosterone levels below International Olympic Committeestandards. The study also found that biological males who suppress their testosterone levels can retain and rebuild their muscle mass, power, and strength through training.

Some, like McKinnon, say transgender athletes should be able to compete according to their gender identity and without suppressing their testosterone levels. They might counter any arguments about unfairness by pointing to Eastwood's performance at the Big Sky cross-country championships on Nov. 2: He placed eighth proof that biological males are not automatically better than biological women in head-to-head competition.

However, Eastwood never placed higher than 24that a Big Sky championship meet when running against men. In other words, even if he wasn't faster than every woman who competed on Nov. 2, he was still faster than most and he displaced one from earning all-conference honors.

In light of the study's findings, the only real way to ensure competitive fairness in women's sports is to keep men out.

Published with permission from WORLD Magazine.

Continued here:
Why men who compete as female will always have an unfair advantage over real women - Lifesite

The film follows Carroll Shelby (played by Matt Damon), a retired driver turned engineer who is contracted by the execs Henry Ford II (Tracy Letts) and Lee Iacocca (Jon Bernthal) to build out Fords racing division. Shelby brings aboard Ken Miles (Christian Bale), a stubborn Brit with a colossal chip on his shoulder and an attitude far from the anodyne politeness thats expected at Ford. Much of the movies two-and-a-half-hour running time revolves around Shelbys corporate battles to convince his bosses that Miles belongs in the drivers seat. But the heart of the film is in the oily garages below the executive suites, where Fords mechanics and drivers strive to create a machine worthy of challenging Ferraris perfection.

Whenever Mangold and his cinematographer Phedon Papamichael are shooting racing footage, Ford v Ferrari practically vibrates off the screen. Car racing in the 1960s was still intense and raw (the technology behind functioning brakes was primitive at best), and Mangold works to convey just how death-defying and brutal the day-long Le Mans race was for a driver. Fords offices, meanwhile, are burnished and beautiful tableaus of mid-century modernity, expensive-looking exhibitions of American wealth that are just as crucial to the companys image as the factory floor. Letts gives a quietly nasty performance as Ford II, emphasizing the CEOs vanity and churlishness as much as the resources at his disposal.

The biggest conflict in Ford v Ferrari isnt the automakers contest, but Shelby and Miless struggle to maintain their integrity while pleasing their corporate overlords. Amid all the testosterone, characters like Mollie Miles (Caitriona Balfe), Kens wife, have few opportunities to shine. Though the script (by Jason Keller and Jez and John-Henry Butterworth) tries to give Balfe a few scenes that assert her personality, shes largely confined to the stock role of frustrated but supportive partner. Noah Jupe, who plays Ken and Mollies plucky son, Peter, gets similarly lost.

Still, the climax of the film, which details all the unpredictable twists of the race itself, brings home the themes Mangold has been working to flesh out. Ford v Ferrari couldve been an easy tale of a dark horse winning against a runaway sporting favorite, but the reality of the 1966 Le Mans contest was much stranger. The movie rejects hackneyed storytelling tropes to depict the limits of ingenuity in the face of capitalistic might, and the result is a rich crowd-pleaser with a pessimistic edge.

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.

See the original post:
Ford v Ferrari: A Rollicking Tale of Fast Cars and Capitalism - The Atlantic

The researchers conducted the study to evaluate whether the clinical prescription of testosterone therapy was associated with short-term risk of venous thromboembolism in men with and without hypogonadism or not. They found that Testosterone therapy is associated with increased risk for venous thromboembolism (VTE) in men. The case-crossover study has been published in JAMA Internal Medicine.

According to the American Heart Association, Venous thromboembolism (VTE) refers to a blood clot that starts in a vein. It is the third leading vascular diagnosis after a heart attack and stroke and includes Deep vein thrombosis andPulmonary embolism .

The researchers used insurance claims databases, researchers identified roughly 40,000 men without cancer whod experienced a VTE. Out of them, nearly 8% were diagnosed with hypogonadism. Each patient served as his own control. The immediate 6 months before the VTE was the case period, and the 6 months before that was the control period.

................................ Advertisement ................................

A claim for testosterone therapy was more common in the 6 months before VTE, compared with the control period, both for men without hypogonadism (0.8% for case period vs. 0.5% for control period) and for those with (34% vs. 22%).

It was found that the use of testosterone therapy in the 6-month case period was associated with an increased risk of venous thromboembolism among men with and without hypogonadism. The testosterone prescription during the case period was associated with roughly double the risk for VTE. The risk was highest in the first 3 months of starting testosterone.

................................ Advertisement ................................

The authors concluded that testosterone therapy was associated with an increase in short-term risk for VTE among men with and without hypogonadism, with some evidence that the association was more pronounced among younger men. These findings suggest that caution should be used when prescribing testosterone therapy.

For further reference log on to:

JAMA Intern Med.Published online November 11, 2019. doi:https://doi.org/10.1001/jamainternmed.2019.5135

Link:
Testosterone therapy prescription linked to increased VTE risk in JAMA study - Specialty Medical Dialogues

Testosterone Replacement Therapy Market to 2024: Deep Analysis

The report offers a complete research study of the globalTestosterone Replacement Therapy Marketthat includes accurate forecasts and analysis at global, regional, and country levels. It provides a comprehensive view of the global Testosterone Replacement Therapy market and detailed value chain analysis to help players to closely understand important changes in business activities observed across the industry. It also offers a deep segmental analysis of the global Testosterone Replacement Therapy market where key product and application segments are shed light upon. Readers are provided with actual market figures related to the size of the global Testosterone Replacement Therapy market in terms of value and volume for the forecast period 2019-2024.

The following Companies as theKey playersin the Global Testosterone Replacement Therapy Market Research Report are AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals.

Free Sample Report + All Related Graphs & Charts @ https://www.acquiremarketresearch.com/sample-request/229964/

Market Overview of Global Testosterone Replacement Therapy

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split intoGels, Injections, Patches.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Hospitals, Clinics.

Geographically, The Testosterone Replacement Therapy market report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering:North America, Europe, China, Japan and others.

Grab Your Report at an Impressive Discount (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/discount-request/229964/

Furthermore, Global Testosterone Replacement Therapy Market following points are involved along with a detailed study of each point:

Major Players:The report provides company profiling for a decent number of leading players of the global Testosterone Replacement Therapy market. It brings to light their current and future market growth taking into consideration their price, gross margin, revenue, production, areas served, production sites, and other factors.

Testosterone Replacement Therapy Market Dynamics:The report shares important information on influence factors, market drivers, challenges, opportunities, and market trends as part of market dynamics.

Global Testosterone Replacement Therapy Market Forecast:Readers are provided with production and revenue forecasts for the global Testosterone Replacement Therapy market, production and consumption forecasts for regional markets, production, revenue, and price forecasts for the global Testosterone Replacement Therapy market by type, and consumption forecast for the global Testosterone Replacement Therapy market by application.

Regional Market Analysis:It could be divided into two different sections: one for regional production analysis and the other for regional consumption analysis. Here, the analysts share gross margin, price, revenue, production, CAGR, and other factors that indicate the growth of all regional markets studied in the report.

Testosterone Replacement Therapy Market Competition:In this section, the report provides information on Competitive situations and trends including merger and acquisition and expansion, market shares of the top three or five players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

Get Customized Report in your Inbox within 24 hours at: https://www.acquiremarketresearch.com/enquire-before/229964/

Significant Facts around Testosterone Replacement Therapy Market Report:

This study uncovers Testosterone Replacement Therapy business summary, item impression, market analysis, distribution networks breakdown, demand, and supply proportion and import/export subtleties. The Industry report highlights distinctive methodologies and methodology supported by the Testosterone Replacement Therapy market key players to settle on imperative business choices. Testosterone Replacement Therapy market describes few parameters, for example, production assessment, Testosterone Replacement Therapy marketing strategies, Distributors/Traders and impact factors are additionally referenced in this Testosterone Replacement Therapy research report.

Browse the full report Description, TOC and Table of Figure @ https://www.acquiremarketresearch.com/industry-reports/testosterone-replacement-therapy-market/229964/

Customization Available

With the given market data, Researchers offer customization according to the companys specific needs. The following customization options are available for the report:

Regional and country-level analysis of the Testosterone Replacement Therapy market, by end-use.

Detailed analysis and profiles of additional market players.

Link:
Value and Size Of Testosterone Replacement Therapy Market From 2019 To 2024: Detailed Research Report - The Denton Chronicle

Share this Article

You are free to share this article under the Attribution 4.0 International license.

A new book traces the origins of the claim that boys will be boysand refutes it.

Thirty years ago, in downtown Mexico City, Matthew Gutmann took a picture of a man holding a baby. Little did he know then that photo would launch a decades-long career studying men and masculinity around the world.

I showed that photo to a bunch of people in the United States, and I kept getting vehement reactions, says Gutmann, a professor of anthropology at Brown University.

People said, This is unreal. This is an aberration. I tried to explain to an art editor at a university press that the photo was candid and not posed, and he says, Thats impossible. Mexican men are machos; they dont carry babies.'

For Gutmann, that moment launched a quest to learn more about men and masculinity in Mexico. He has since studied the state of sexual and reproductive health across Latin America, investigated the concept of masculine loyalty among American veterans who fought in Iraq, and observed changes in workplace gender standards in urban China, where he currently teaches as a visiting professor.

In some ways, the book Are Men Animals? (Basic Books, 2019) is a distillation of all that Gutmann has learned since he took that fateful photo as a graduate student. His book takes the reader on a world tour, examining the women-only subway cars of Mexico City, the barrio of Santo Domingo and the so-called marriage market in Shanghai to demonstrate that theres no single definition of masculinity or manliness.

Ultimately, Gutmann says, he hopes Are Men Animals? emphasizes that men are more than testosterone and Y chromosomesthat theyre made as much by society as by biology.

The great feminist Simone de Beauvoir once wrote about women, Their biology is not their destiny,' Gutmann says. I think we need to say something similar about men. Mens biology is not their destiny, either.

Ahead of the release of Are Men Animals?, Gutmann answered a few questions about the book, his research, and the future of masculinity:

Original Study

Excerpt from:
New book refutes 'boys will be boys' - Futurity: Research News

Global Testosterone Replacement Therapy market report is the first of its kind research report that covers the overview, market dynamics, competitive analysis, and leading players numerous strategies to sustain in the global market. This report covers five top regions of the world and countries within, which shows the status of regional development, consisting of volume, size, market value, and price data.

The report takes a dashboard view of an entire Testosterone Replacement Therapy market by comprehensively analyzing market circumstance and situation and the various activities of leading players in the market such as mergers, partnerships, and acquisitions. This unique report explains the present industry situations that give the crystal-clear picture of the global Testosterone Replacement Therapy market to the clients.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): http://researchindustry.us/report/testosterone-replacement-therapy-market-ric/759945/request-sample

Market Segmentation

Key players considered in the report include

AbbVieEndo InternationalEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals

On the basis of types, the global Testosterone Replacement Therapy market is primarily split into

GelsInjectionsPatchesOther

Based on application, the global Testosterone Replacement Therapy market is primarily split into

HospitalsClinicsOthers

Some of the significant factors such as marketing strategy, factor analysis, cost analysis, industrial chain, distributors and sourcing strategy are included in this report which makes it an exclusive one. The report on the global Testosterone Replacement Therapy market report is compiled by industry experts and properly examined which will highlight the key information required by the clients.

Regional Analysis

A unit of the report has given comprehensive information about regional analysis. It provides a market outlook and sets the forecast within the context of the overall global Testosterone Replacement Therapy market. Research Industry US has segmented the global Testosterone Replacement Therapy market into major geographical regions such as North America, Europe, Asia Pacific, South America, and the Middle East and Africa (MEA). Potential new entrants wishing to target only high growth areas are also included in this informative section of the global Testosterone Replacement Therapy market.

Based on geography, the global Testosterone Replacement Therapy market is divided into North America, Europe, Asia-Pacific, South America, and The Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. India, China, Japan, South Korea, and Rest of Asia-Pacific are the categorization of the Asia-Pacific region. The South America region includes Brazil, Argentina, and the Rest of South America, while The Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and the Rest of the Middle East & Africa.

Enquire Here For Queries Or Report Customization: http://researchindustry.us/report/testosterone-replacement-therapy-market-ric/759945/request-customization

Following queries are answered in the Testosterone Replacement Therapy report:-

Get In Touch!

Navale ICON IT Park,

Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, Pune

Maharashtra 411041

phone +91-020-67320403

Email [emailprotected]

Research Industry

Research Industry USA is a market research and consultative company that provides market research reports and business insights to large and small & medium enterprises. The company supports its clients to conceive business policies and accomplish sustainable growth in their particular market domain. We meet clients objectives, commitment and dedication on high standard and targeting possible prospects for market research reports.

Follow this link:
Testosterone Replacement Therapy Market 2019| Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2026 | Research Industry US...

AMA recently published a detailed study of over 180+ pages in its repository on Testosterone Replacement Therapy market covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are AbbVie Inc. (United States), Endo International (Ireland), Eli Lilly and Company (United States), Pfizer (United States), Bayer (Germany), Actavis (Allergan) (United States), Novartis (Switzerland), Teva (Israel), Ferring Pharmaceuticals (Switzerland), Kyowa Kirin (Japan), Mylan (United States)

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market @ https://www.advancemarketanalytics.com/sample-report/46424-global-testosterone-replacement-therapy-market

Testosterone is responsible for the development of male sexual characteristics and this hormone formed by the testicles. Insufficient production of testosterone causes erectile dysfunction. Testosterone Replacement Therapy (TRT) is generally termed as hormone therapy for men, designed to counteract the effects of reduced activity in the gonads or hypogonadism. Hypogonadism in men is clinical syndrome, which results in the failure of the testes to produce physiological levels of testosterone. Erectile dysfunction arises due to reduce testosterone production to overcome this testosterone replacement therapy is used to improve the problem.

Market Segmentationby Type (Creams or Gels, Patches, Injections, Buccal Adhesives, Implants, Oral), Application (Hospitals, Clinics)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/46424-global-testosterone-replacement-therapy-market

Whats Trending in Market: Increasing awareness about testosterone substitute therapy

Growth Drivers: Increasing prevalence of hypogonadism in adult men

The need for having an offspring amongst men

Restraints: High possibility of side effects related to testosterone replacement therapy

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/46424-global-testosterone-replacement-therapy-market

Country level Break-up includes:North America (United States, Canada and Mexico)Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Try a limited scope research document specific to Country or Regional matching your objective.

GET FULL COPY OF United States Testosterone Replacement Therapy market study @ USD 2000

And, Europe Testosterone Replacement Therapy market study @ USD 2500 Major Highlights of TOC:

Chapter One: Market Overview

Scope/Objective of the Study

Chapter Two: Executive Summary - Free of Cost

Chapter Three: Market Dynamics USD400

Market Drivers, Market Challenges, Market Trends

Chapter Four: Market Factor Analysis USD400

Supply/Value Chain Analysis, Porters Five Forces, PESTEL analysis, Market Entropy, Patent & Trademark Analysis, Market Development Scenario

Chapter Five and Seven: Global Testosterone Replacement Therapy, by Market Segmentation and Region (value, volume**) (2013-2024) USD2400

Global Testosterone Replacement Therapy

By Type (Creams or Gels, Patches, Injections, Buccal Adhesives, Implants, Oral)

By Application (Hospitals, Clinics)

Global Testosterone Replacement Therapy Region

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Chapter Six: Global Testosterone Replacement Therapy Manufacturers/Players Analysis USD1200

Competitive Landscape (Direct & Indirect Competitors), Market Share Analysis, Peer Group Analysis (2018), BCG Matrix, Company Profile, Downstream Buyers & Upstream Suppliers

..

Chapter Nine: Methodology/Research Approach, Data Source, Disclaimer

** If applicable

* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=46424

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us: CRAIG FRANCIS (PR & Marketing Manager)[emailprotected]Ph: +1 (206) 317 1218

See more here:
Testosterone Replacement Therapy Industry: Time to Invest in emerging Markets | Endo International, Pfizer, Novartis - News Description

Page 88«..1020..87888990..100..»

Home » Testosterone » Page 88